| Name: | Alogliptin N Formyl Carbamoyl Impurity |
| Catalogue No. | VL5900046 |
| CAS No. | N/A |
| Molecular Formula | C19H23N5O4 |
| Molecular Weight | 385.42 g/mol |
| Status | In-Stock |
| IUPAC Name | (R)-2-((6-(3-formamidopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzamide |
| Description | Alogliptin N Formyl Carbamoyl Impurity(CAS No: N/A) or (R)-2-((6-(3-formamidopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzamide,it has capability to reduce blood glucose levels in type-2 diabetes, 20% bound to plasma protein binding and it does not undergo extensive metabolism |
| References | Kaku, Kohei, et al. “Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus.” Drug Safety, vol. 42, no. 11, 25 Oct. 2019, pp. 1311–1327, 10.1007/s40264-019-00857-8. |
